TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
Medtronic large thin body, its 23 kinds of products to sell
 
Author:中国铭铉 企划部  Release Time:2017-4-20 11:30:23  Number Browse:479
 
Medical network on April 20 - medtronic "slimming" come true. 
 
According to Reuters news, American drug dealers Kant le (Cardinal Health) announced on Tuesday, will be $6.1 billion medtronic some medical supplies business, mode of payment in cash. 
 
Medtronic to sell this patient care, deep vein thrombosis and nutritional function completion department, the business covers 23 of the across multiple market product categories, including Curity, Kendall, Dover, Argyle and brands such as the Kangaroo. 
 
It is important to note that the above mentioned brand originally is covidien medical unit. 
 
Curity for medical catheter products; Kendall for antithrombotic pressure pump/bag series product, used for the field of prevention and cure of venous dysfunction; Dover for urinary catheter products; Argyle for peritoneal dialysis tube and accessories products; The Kangaroo, Kangaroo brand enteral nutrition pump and series of products, can say is a classic brand in the field of enteral nutrition pathways. 
 
In 2014, medtronic announced $42.9 billion acquisition of covidien medical case become the largest acquisition in the global medical device industry. But with abbott gains later st Jude as part of the business, medtronic began taking covidien parts of the business. 
 
Medtronic says, overall, the sales department in the past four quarters to create business revenue of $2.4 billion or so. 
 
And once the transaction come true, all products will be classified Kant's. Kant has a strong distribution network, there are many direct marketing and logistics company in China, the related products should be able to share. 
 
Previous article:All cancelled after drug addition Public hospitals rely on what "live"
Next article:114 listed companies last year performance prediction increases the pharmaceutical industry to decline in income growth "cold winter"
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粤公网安备 44011202000029号